SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cohen S, Carpenter G. Human epidermal growth factor: isolation and chemical and biologic properties. Proc Natl Acad Sci U S A. 1975;72:13171321.
  • 2
    Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem. 1979;48:193216.
  • 3
    Sqambato A, Casaluce F, Maione P, et al. The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer patients harboring EGFR mutations. Curr Med Chem. 2012;19:33373352.
  • 4
    Hirsch FR, Janne PA, Eberhardt WE, et al. Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol. 2013;8:373384.
  • 5
    Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013;31:10391049.
  • 6
    Malapelle U, Bellevicine C, De Luca C, et al. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung cancer patients. Cancer Cytopathol. 2013;121:552560.
  • 7
    National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Nonsmall cell lung cancer, version 2.2013 {pg 66 MS-6; pg 81 MS-21}. Available at: www.nccn.org/professionals/physicians_gls/f_guidelines.asp. Accessed June 3, 2013.
  • 8
    Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association of Molecular Pathology [published online ahead of print April 4, 2013]. J Mol Diagn. 2013.
  • 9
    Clinical and Laboratory Standards Institute (CLSI). Molecular Methods for Clinical Genetics and Oncology Testing: Approved Guideline. 3rd ed. CLSI Document MM01-A3. Wayne, PA: CLSI; 2012.
  • 10
    Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Arch Pathol Lab Med. 2013;137:668684.
  • 11
    Rivera MP, Mehta AC. Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 suppl):131S148S.
  • 12
    Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol. 2011;6:451458.
  • 13
    Wong C, DiCioccio RA, Allen HJ, et al. Mutations in BRCA1 from formalin-fixed, paraffin-embedded tissue can be artifacts of preservation. Cancer Genet Cytogenet. 1998;107:2127.
  • 14
    Williams C, Ponten F, Moberg C, et al. A high frequency of sequence alterations is due to formalin fixation in of archival specimens. Am J Pathol. 199;155:14671471.
  • 15
    Akbari N, Hansen MD, Halgunset J, et al. Low copy number DNA template can render polymerase chain reaction error prone in a sequence-dependent manner. J Mol Diagn. 2005;7:3639.
  • 16
    Aisner DL, Deshpande C, Baloch Z, et al. Evaluation of EGFR mutation status in cytology specimens: an institutional experience. Diagn Cytopathol. 2013;41:316323.
  • 17
    da Cunha Santos G, Saieg MA, Geddie W, Leighl N. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer Cytopathol. 2011;119:8091.
  • 18
    Su Z, Ning B, Fang H, et al. Next-generation sequencing and its applications in molecular diagnostics. Expert Rev Mol Diagn. 2011;11:333343.
  • 19
    Buttitta F, Felicioni LDel Grammastro M, et al. Effective assessment of EGFR mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. Clin Cancer Res. 2013;19:691698.
  • 20
    Peled N, Palmer G, Hirsch FR, et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small cell lung cancer. J Thorac Oncol. 2012;7:e14e16.